{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:01Z","timestamp":1794045781319,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL095685"],"award-info":[{"award-number":["R01 HL095685"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL149893"],"award-info":[{"award-number":["R01 HL149893"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic inflammation is frequently associated with myeloproliferative neoplasms (MPN), but the role of inflammation in the pathogenesis of MPN remains unclear. Expression of the proinflammatory cytokine interleukin-1 (IL-1) is elevated in patients with MPN as well as in Jak2V617F knock-in mice. Here, we show that genetic deletion of IL-1 receptor 1 (IL-1R1) normalizes peripheral blood counts, reduces splenomegaly and ameliorates bone marrow fibrosis in homozygous Jak2V617F mouse model of myelofibrosis. Deletion of IL-1R1 also significantly reduces Jak2V617F mutant hematopoietic stem\/progenitor cells. Exogenous administration of IL-1\u03b2 enhances myeloid cell expansion and accelerates the development of bone marrow fibrosis in heterozygous Jak2V617F mice. Furthermore, treatment with anti-IL-1R1 antibodies significantly reduces leukocytosis and splenomegaly, and ameliorates bone marrow fibrosis in homozygous Jak2V617F mice. Collectively, these results suggest that IL-1 signaling plays a pathogenic role in MPN disease progression, and targeting of IL-1R1 could be a useful strategy for the treatment of myelofibrosis.<\/jats:p>","DOI":"10.1038\/s41467-022-32928-3","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T10:23:33Z","timestamp":1663064613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm"],"prefix":"10.1038","volume":"13","author":[{"given":"Mohammed Ferdous-Ur","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0368-2858","authenticated-orcid":false,"given":"Avik","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Posyniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Faughnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9903-6959","authenticated-orcid":false,"given":"Mohammad A.","family":"Sayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine S.","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7530-4784","authenticated-orcid":false,"given":"Golam","family":"Mohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"32928_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker, W. & Kralovics, R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129, 667\u2013679 (2017).","journal-title":"Blood"},{"key":"32928_CR2","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488\u20132498 (2014).","journal-title":"N. Engl. J. Med."},{"key":"32928_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.stem.2021.02.001","volume":"28","author":"D Van Egeren","year":"2021","unstructured":"Van Egeren, D. et al. Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms. Cell. Stem Cell. 28, 514\u2013523 (2021).","journal-title":"Cell. Stem Cell."},{"key":"32928_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","volume":"602","author":"N Williams","year":"2022","unstructured":"Williams, N. et al. Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature 602, 162\u2013168 (2022).","journal-title":"Nature"},{"key":"32928_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi, A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am. J. Hematol. 96, 145\u2013162 (2021).","journal-title":"Am. J. Hematol."},{"key":"32928_CR6","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/leu.2016.12","volume":"30","author":"S Koschmieder","year":"2016","unstructured":"Koschmieder, S. et al. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia 30, 1018\u20131024 (2016).","journal-title":"Leukemia"},{"key":"32928_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","volume":"24","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch, H. C. et al. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev. 24, 133\u2013145 (2013).","journal-title":"Cytokine Growth Factor Rev."},{"key":"32928_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.exphem.2012.05.011","volume":"40","author":"V Skov","year":"2012","unstructured":"Skov, V. et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp. Hematol. 40, 771\u2013780 (2012).","journal-title":"Exp. Hematol."},{"key":"32928_CR9","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","volume":"95","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson, S. Y., Landgren, O., Samuelsson, J., Bj\u00f6rkholm, M. & Goldin, L. R. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 95, 1216\u20131220 (2010).","journal-title":"Haematologica"},{"key":"32928_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello, C. A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev. 281, 8\u201327 (2018).","journal-title":"Immunol. Rev."},{"key":"32928_CR11","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","volume":"50","author":"A Mantovani","year":"2019","unstructured":"Mantovani, A., Dinarello, C. A., Molgora, M. & Garlanda, C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity 50, 778\u2013795 (2019).","journal-title":"Immunity"},{"key":"32928_CR12","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1084\/jem.187.9.1463","volume":"187","author":"R Horai","year":"1998","unstructured":"Horai, R. et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha\/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187, 1463\u20131475 (1998).","journal-title":"J. Exp. Med."},{"key":"32928_CR13","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.4049\/jimmunol.159.7.3364","volume":"159","author":"MB Glaccum","year":"1997","unstructured":"Glaccum, M. B. et al. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J. Immunol. 159, 3364\u20133371 (1997).","journal-title":"J. Immunol."},{"key":"32928_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ncb3346","volume":"18","author":"EM Pietras","year":"2016","unstructured":"Pietras, E. M. et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat. Cell Biol. 18, 607\u2013618 (2016).","journal-title":"Nat. Cell Biol."},{"key":"32928_CR15","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi, A. et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J. Clin. Oncol. 29, 1356\u20131363 (2011).","journal-title":"J. Clin. Oncol."},{"key":"32928_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ajh.23295","volume":"87","author":"R Vaidya","year":"2012","unstructured":"Vaidya, R. et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am. J. Hematol. 87, 1003\u20131005 (2012).","journal-title":"Am. J. Hematol."},{"key":"32928_CR17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med"},{"key":"32928_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00281-016-0559-z","volume":"38","author":"LA Borthwick","year":"2016","unstructured":"Borthwick, L. A. The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin Immunopathol. 38, 517\u2013534 (2016).","journal-title":"Semin Immunopathol."},{"key":"32928_CR19","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.3390\/ijms21176009","volume":"21","author":"V Gelfo","year":"2020","unstructured":"Gelfo, V. et al. Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies. Int J. Mol. Sci. 21, 6009 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"32928_CR20","doi-asserted-by":"publisher","first-page":"102617","DOI":"10.1016\/j.autrev.2020.102617","volume":"19","author":"P Migliorini","year":"2020","unstructured":"Migliorini, P., Italiani, P., Pratesi, F., Puxeddu, I. & Boraschi, D. The IL-1 family cytokines and receptors in autoimmune diseases. Autoimmun. Rev. 19, 102617 (2020).","journal-title":"Autoimmun. Rev."},{"key":"32928_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019000519","volume":"134","author":"F Schischlik","year":"2019","unstructured":"Schischlik, F. et al. Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood 134, 199\u2013210 (2019).","journal-title":"Blood"},{"key":"32928_CR22","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","volume":"115","author":"H Akada","year":"2010","unstructured":"Akada, H. et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115, 3589\u20133597 (2010).","journal-title":"Blood"},{"key":"32928_CR23","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/leu.2014.52","volume":"28","author":"H Akada","year":"2014","unstructured":"Akada, H., Akada, S., Hutchison, R. E. & Mohi, G. Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice. Leukemia 28, 1627\u20131635 (2014).","journal-title":"Leukemia"},{"key":"32928_CR24","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41375-021-01464-2","volume":"36","author":"A Dutta","year":"2022","unstructured":"Dutta, A. et al. Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models. Leukemia 36, 746\u2013759 (2022).","journal-title":"Leukemia"},{"key":"32928_CR25","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1126\/science.7660125","volume":"269","author":"R K\u00fchn","year":"1995","unstructured":"K\u00fchn, R., Schwenk, F., Aguet, M. & Rajewsky, K. Inducible gene targeting in mice. Science 269, 1427\u20131429 (1995).","journal-title":"Science"},{"key":"32928_CR26","doi-asserted-by":"publisher","first-page":"e0150068","DOI":"10.1371\/journal.pone.0150068","volume":"11","author":"MJ Robson","year":"2016","unstructured":"Robson, M. J. et al. Generation and characterization of mice expressing a conditional allele of the interleukin-1 receptor type 1. PLoS One 11, e0150068 (2016).","journal-title":"PLoS One"},{"key":"32928_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.stem.2015.07.007","volume":"17","author":"S Haas","year":"2015","unstructured":"Haas, S. et al. Inflammation-induced emergency megakaryopoiesis driven by hematopoietic stem cell-like megakaryocyte progenitors. Cell Stem Cell 17, 422\u2013434 (2015).","journal-title":"Cell Stem Cell"},{"key":"32928_CR28","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/cells11040680","volume":"11","author":"JS Chavez","year":"2022","unstructured":"Chavez, J. S. et al. PU.1 expression defines distinct functional activities in the phenotypic HSC compartment of a murine inflammatory stress model. Cells 11, 680 (2022).","journal-title":"Cells"},{"key":"32928_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.exphem.2018.09.004","volume":"68","author":"SB Hay","year":"2018","unstructured":"Hay, S. B., Ferchen, K., Chetal, K., Grimes, H. L. & Salomonis, N. The Human Cell Atlas bone marrow single-cell interactive web portal. Exp. Hematol. 68, 51\u201361 (2018).","journal-title":"Exp. Hematol."},{"key":"32928_CR30","doi-asserted-by":"publisher","first-page":"D780","DOI":"10.1093\/nar\/gky1020","volume":"47","author":"J Choi","year":"2019","unstructured":"Choi, J. et al. Haemopedia RNA-seq: a database of gene expression during haematopoiesis in mice and humans. Nucleic Acids Res. 47, D780\u2013D785 (2019).","journal-title":"Nucleic Acids Res."},{"key":"32928_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/ni.2587","volume":"14","author":"V Jojic","year":"2013","unstructured":"Jojic, V. et al. Identification of transcriptional regulators in the mouse immune system. Nat. Immunol. 14, 633\u2013643 (2013).","journal-title":"Nat. Immunol."},{"key":"32928_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/gene.10092","volume":"33","author":"M Logan","year":"2002","unstructured":"Logan, M. et al. Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis 33, 77\u201380 (2002).","journal-title":"Genesis"},{"key":"32928_CR33","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32928_CR34","doi-asserted-by":"publisher","first-page":"e20200560","DOI":"10.1084\/jem.20200560","volume":"218","author":"KC Higa","year":"2021","unstructured":"Higa, K. C. et al. Chronic interleukin-1 exposure triggers selection for Cebpa-knockout multipotent hematopoietic progenitors. J. Exp. Med. 218, e20200560 (2021).","journal-title":"J. Exp. Med."},{"key":"32928_CR35","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1182\/blood-2013-12-544197","volume":"124","author":"R Norfo","year":"2014","unstructured":"Norfo, R. et al. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155\/JARID2 axis in abnormal megakaryopoiesis. Blood 124, e21\u2013e32 (2014).","journal-title":"Blood"},{"key":"32928_CR36","doi-asserted-by":"crossref","unstructured":"Yao, J. C. et al. TGF-\u03b2 signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche. J. Clin. Invest. 132, e154092 (2022).","DOI":"10.1172\/JCI154092"},{"key":"32928_CR37","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","volume":"20","author":"RK Schneider","year":"2017","unstructured":"Schneider, R. K. et al. Gli1+ mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target. Cell Stem Cell 20, 785\u2013800.e788 (2017).","journal-title":"Cell Stem Cell"},{"key":"32928_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature13383","volume":"512","author":"L Arranz","year":"2014","unstructured":"Arranz, L. et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 512, 78\u201381 (2014).","journal-title":"Nature"},{"key":"32928_CR39","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2014-12-618595","volume":"126","author":"M Lu","year":"2015","unstructured":"Lu, M. et al. Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood 126, 972\u2013982 (2015).","journal-title":"Blood"},{"key":"32928_CR40","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.molimm.2010.10.016","volume":"48","author":"J Batliner","year":"2011","unstructured":"Batliner, J. et al. CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation. Mol. Immunol. 48, 714\u2013719 (2011).","journal-title":"Mol. Immunol."},{"key":"32928_CR41","doi-asserted-by":"publisher","first-page":"18757","DOI":"10.1074\/jbc.TM118.003336","volume":"293","author":"AS Bachmann","year":"2018","unstructured":"Bachmann, A. S. & Geerts, D. Polyamine synthesis as a target of MYC oncogenes. J. Biol. Chem. 293, 18757\u201318769 (2018).","journal-title":"J. Biol. Chem."},{"key":"32928_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature22314","volume":"545","author":"A Hattori","year":"2017","unstructured":"Hattori, A. et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature 545, 500\u2013504 (2017).","journal-title":"Nature"},{"key":"32928_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.542","volume":"6","author":"A Modelska","year":"2015","unstructured":"Modelska, A. et al. The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape. Cell Death Dis. 6, e1603 (2015).","journal-title":"Cell Death Dis."},{"key":"32928_CR44","first-page":"cm1","volume":"3","author":"A Weber","year":"2010","unstructured":"Weber, A., Wasiliew, P. & Kracht, M. Interleukin-1 (IL-1) pathway. Sci. Signal 3, cm1 (2010).","journal-title":"Sci. Signal"},{"key":"32928_CR45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/cvr\/cvt258","volume":"101","author":"L Wang","year":"2014","unstructured":"Wang, L. et al. Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation. Cardiovasc Res 101, 383\u2013392 (2014).","journal-title":"Cardiovasc Res"},{"key":"32928_CR46","first-page":"3786","volume":"117","author":"P Gasse","year":"2007","unstructured":"Gasse, P. et al. IL-1R1\/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J. Clin. Invest 117, 3786\u20133799 (2007).","journal-title":"J. Clin. Invest"},{"key":"32928_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe, M. et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell 33, 29\u201343 (2018).","journal-title":"Cancer Cell"},{"key":"32928_CR48","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"A Daniel","year":"2019","unstructured":"Daniel, A. et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling. Leukemia 33, 1978\u20131995 (2019).","journal-title":"Leukemia"},{"key":"32928_CR49","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","volume":"128","author":"B Zhang","year":"2016","unstructured":"Zhang, B. et al. Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. Blood 128, 2671\u20132682 (2016).","journal-title":"Blood"},{"key":"32928_CR50","doi-asserted-by":"publisher","unstructured":"Rai, S. et al. Inhibition of interleukin-1\u03b2 reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. https:\/\/doi.org\/10.1038\/s41467-022-32927-4.","DOI":"10.1038\/s41467-022-32927-4"},{"key":"32928_CR51","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1006\/cimm.2001.1895","volume":"214","author":"BC Schaefer","year":"2001","unstructured":"Schaefer, B. C., Schaefer, M. L., Kappler, J. W., Marrack, P. & Kedl, R. M. Observation of antigen-dependent CD8+ T-cell\/ dendritic cell interactions in vivo. Cell Immunol. 214, 110\u2013122 (2001).","journal-title":"Cell Immunol."},{"key":"32928_CR52","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/blood-2016-12-757344","volume":"130","author":"A Dutta","year":"2017","unstructured":"Dutta, A., Hutchison, R. E. & Mohi, G. Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF-\u03b21 and Cxcl12 pathways. Blood 130, 920\u2013932 (2017).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32928-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32928-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32928-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T22:30:17Z","timestamp":1676759417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32928-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32928"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32928-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"9 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.M. received research funding from the Erasca Inc. in a project outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5347"}}